您当前的位置：首页 >> 正文

生长抑素联合乌司他丁治疗消化道出血的Meta分析 [中文引用][英文引用]

Meta analysis of somatostatin combined with ulinastatin in the treatment of gastrointestinal bleeding

[HTML下载] [PDF下载] [发表评论] [查看评论] [加入收藏] [ 370 人次已阅读该文]

作者：周嫏嬛1龚伟玲2孙孚春1宋颂1

作者(英文)：

单位：山东省青岛市城阳区人民医院临床药学科1 北京联勤保障部队药品仪器监督检验总站药品安全监督科2

单位(英文)：

关键词：消化道出血乌司他丁生长抑素 Meta分析

关键词(英文)：Gastrointestinal bleeding Ulinastatin Somatostatin Meta analysis

分类号：

出版年·卷·期（页码）：2023·1·第1期（26-32）

DOI: 10.3877/cma.j.issn.2095-2015.2023.01.006

-----摘要：-------------------------------------------------------------------------------------------

【摘要】目的：系统评价生长抑素联合乌司他丁治疗消化道出血的有效性和安全性。方法：计算机检索中国知网、维普、万方、CBM、PubMed、Cochorane library、Embase数据库，搜集有关生长抑素联合乌司他丁治疗消化道出血的随机对照试验。使用Revman 5.3软件进行Mete分析。结果：共纳入16项研究，1466例患者。结果显示，在总有效率[RR=1.24,95%CI(1.19~1.31)，P＜0.00001]、白细胞介素-2[SMD=1.10,95%CI(0.38~1.81)，P=0.003]、白细胞介素-6[SMD=-3.40,95%CI(-4.69~-2.12)，P＜0.00001]、白细胞介素-10[SMD=2.77,95%CI(1.66~3.87)，P＜0.00001]、肿瘤坏死因子-α[SMD=-2.56,95%CI(-3.26~-1.87)，P＜0.00001]、住院时间[SMD=-1.75,95%CI(-2.24~-1.26)，P＜0.00001]、消化道出血时间[SMD=-3.55,95%CI(-4.11~-2.99)，P＜0.00001]方面，生长抑素联合乌司他丁治疗明显优于单用生长抑素治疗。在不良反应发生率方面，两组差异无统计学意义[SMD=0.79,95%CI(0.47~1.32)，P=0.38]，且均较低。结论：生长抑素联合乌司他丁治疗消化道出血是安全、有效的，但亟需更多高质量的临床试验加以验证。

-----英文摘要：---------------------------------------------------------------------------------------

[Abstract] Objective To systematically evaluate the efficacy and safety of somatostatin combined with ulinastatin in the treatment of gastrointestinal hemorrhage. Methods CNKI, VIP, Wanfang, CBM database, PubMed, Cochrane Library, EMBase were searched to collect randomized controlled trials of somatostatin combined with ulinastatin in the treatment of gastrointestinal bleeding. Mete analysis was performed using Revman 5.3 software. Results A total of 16 studies involving 1466 patients were included. The results showed that somatostatin combined with ulinastatin was better than somatostatin alone in the total effective rate (RR=1.24, 95%CI: 1.19-1.31, P<0.00001), interleukin-2 (SMD=1.10, 95%CI: 0.38-1.81, P=0.003), interleukin-6 (SMD=﹣3.40, 95%CI: ﹣4.69- ﹣2.12, P<0.00001), interleukin-10 (SMD=2.77, 95%CI: 1.66-3.87, P<0.00001), tumor necrosis factor-α (SMD=﹣2.56, 95%CI: ﹣3.26- ﹣1.87, P<0.00001), hospitalization time (SMD=﹣1.75, 95%CI: ﹣2.24-﹣1.26, P<0.00001) and gastrointestinal hemostasis time (SMD=﹣3.55, 95%CI: ﹣4.11-﹣2.99, P<0.00001). There was no statistically significant difference in the incidence of adverse reactions between the two groups (SMD=0.79, 95%CI: 0.47-1.32, P=0.38), and both were lower. Conclusion Somatostatin combined with ulinastatin in the treatment of gastrointestinal bleeding is safe and effective, but it needs more high-quality clinical trials to verify.

-----参考文献：---------------------------------------------------------------------------------------